Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | CKS1B | P61024 | 1/20 | 0.40 |
| ▸ | SKP1 | P63208 | 1/20 | 0.40 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | CACNA1I | Q9P0X4 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 6/20 | 0.36 |
| ▸ | ACACA | Q13085 | 5/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2989855 | 0.99 | DRD2 (0.43) | DRD2CKS1BSKP1SKP2KDM4E | |
| SCHEMBL1973738 | 0.98 | DRD2 (0.43) | DRD2CKS1BSKP1SKP2KDM4E | |
| SCHEMBL1973209 | 0.90 | DRD2 (0.41) | DRD2CKS1BSKP1SKP2KDM4E | |
| SCHEMBL3295757 | 0.89 | DRD2 (0.44) | DRD2CKS1BSKP1SKP2KDM4E | |
| SCHEMBL3293795 | 0.89 | DRD2 (0.46) | DRD2CKS1BSKP1SKP2KDM4E | |
| SCHEMBL1970862 | 0.88 | KMT2A (0.42) | DRD2CKS1BSKP1SKP2KDM4E | |
| SCHEMBL1972235 | 0.87 | DRD2 (0.44) | DRD2CKS1BSKP1SKP2KDM4E | |
| SCHEMBL1970214 | 0.84 | DRD2 (0.46) | DRD2CKS1BSKP1SKP2KDM4E | |
| SCHEMBL1970171 | 0.80 | DRD2 (0.42) | DRD2CKS1BSKP1SKP2KDM4E | |
| SCHEMBL3294623 | 0.79 | HTR1D (0.39) | DRD2KMT2AEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101522668-B | Oxyindole derivatives as 5ht4 receptor agonists | PFIZER | 2012-06-06 | — | — | CN | disclosed |
| EP-1856110-B1 | OXYINDOLE DERIVATIVES AS 5HT4 RECEPTOR AGONISTS | PFIZER (US) | 2011-06-22 | — | — | EP | disclosed |
| US-20100173925-A1 | OXYINDOLE DERIVATIVES | PFIZER INC | 2010-07-08 | — | — | US | disclosed |
| US-7737163-B2 | Benzimidazolone carboxylic acid derivatives | PFIZER INC. (US) | 2010-06-15 | — | — | US | disclosed |
| US-7705020-B2 | Benzimidazolone carboxylic acid derivatives | PFIZER INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-7595329-B2 | Benzimidazolone carboxylic acid derivatives | PFIZER INC (US) | 2009-09-29 | — | — | US | disclosed |
| US-7589109-B2 | Oxyindole derivatives | PFIZER INC (US) | 2009-09-15 | — | — | US | disclosed |
| CN-101522668-A | Oxyindole derivatives as 5ht4 receptor agonists | PFIZER JAPAN INC (US) | 2009-09-02 | — | — | CN | disclosed |
| US-20080108660-A1 | Benzimidazolone Carboxylic Acid Derivatives | PFIZER INC | 2008-05-08 | — | — | US | disclosed |
| EP-1758891-A2 | BENZIMIDAZOLONE CARBOXYLIC ACID DERIVATIVES | Pfizer Japan Inc. (JP) | 2007-03-07 | — | — | EP | disclosed |
| US-20060194842-A1 | Oxyindole derivatives | PFIZER INC. | 2006-08-31 | — | — | US | disclosed |
| WO-2005123718-A2 | BENZIMIDAZOLONE CARBOXYLIC ACID DERIVATIVES | PFIZER JAPAN INC. (JP) | 2005-12-29 | — | — | WO | disclosed |
| US-20050277672-A1 | Benzimidazolone carboxylic acid derivatives | PFIZER INC | 2005-12-15 | — | — | US | disclosed |
| US-20050277671-A1 | Benzimidazolone carboxylic acid derivatives | PFIZER INC | 2005-12-15 | — | — | US | disclosed |
| US-20050277673-A1 | Benzimidazolone carboxylic acid derivatives | PFIZER JAPAN INC. (JP) | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173925-A1 | OXYINDOLE DERIVATIVES | HTR4, HTR5A, HRH4 | DRD2 146/4885CKS1B 3846/4885SKP1 1679/4885 |
| US-20050277673-A1 | Benzimidazolone carboxylic acid derivatives | HRH2, HRH4, GPR4 | DRD2 1161/4885CKS1B 1713/4885SKP1 796/4885 |
| US-20050277672-A1 | Benzimidazolone carboxylic acid derivatives | HRH2, HRH4, GPR4 | DRD2 1161/4885CKS1B 1713/4885SKP1 796/4885 |
| US-20060194842-A1 | Oxyindole derivatives | HTR4, HTR5A, HRH4 | DRD2 146/4885CKS1B 3846/4885SKP1 1679/4885 |
| US-20050277671-A1 | Benzimidazolone carboxylic acid derivatives | HRH2, HRH4, GPR4 | DRD2 1161/4885CKS1B 1713/4885SKP1 796/4885 |
| US-20080108660-A1 | Benzimidazolone Carboxylic Acid Derivatives | HRH2, HRH4, GPR4 | DRD2 1305/4885CKS1B 1624/4885SKP1 808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.